{"protocolSection": {"identificationModule": {"nctId": "NCT01434186", "orgStudyIdInfo": {"id": "CV181-147"}, "secondaryIdInfos": [{"id": "2010-024568-16", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone", "officialTitle": "A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone"}, "statusModule": {"statusVerifiedDate": "2017-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-05"}, "primaryCompletionDateStruct": {"date": "2016-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-09-13", "studyFirstSubmitQcDate": "2011-09-13", "studyFirstPostDateStruct": {"date": "2011-09-14", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-03-07", "resultsFirstSubmitQcDate": "2017-03-07", "resultsFirstPostDateStruct": {"date": "2017-04-18", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-03-07", "lastUpdatePostDateStruct": {"date": "2017-04-18", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}, "collaborators": [{"name": "Bristol-Myers Squibb", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "To evaluate the efficacy, safety, tolerability, of Saxagliptin (BMS-477118) in combination with Metformin in pediatric patients with type 2 diabetes", "detailedDescription": "A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination with Metformin IR or Metformin XR in Pediatric Patients with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin Alone or in Combination with Baseline Insulin Therapy"}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 32, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Arm 1: Saxagliptin +Metformin XR/IR", "type": "EXPERIMENTAL", "description": "Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight) Metformin XR/IR 1000 mg-2000 mg", "interventionNames": ["Drug: Metformin IR", "Drug: Metformin XR", "Drug: Saxagliptin"]}, {"label": "Arm 2: Placebo +Metformin XR/IR", "type": "PLACEBO_COMPARATOR", "description": "Placebo matching saxagliptin 0 mg Metformin XR/IR 1000 mg - 2000 mg", "interventionNames": ["Drug: Placebo matching with Saxagliptin", "Drug: Metformin IR", "Drug: Metformin XR"]}], "interventions": [{"type": "DRUG", "name": "Placebo matching with Saxagliptin", "description": "Tablet, Oral, 0.0 mg, Daily, Day 1 through week 52", "armGroupLabels": ["Arm 2: Placebo +Metformin XR/IR"]}, {"type": "DRUG", "name": "Metformin IR", "description": "Tablet, Oral, 1000 mg -2000 mg, Daily , Day 1 through week 52", "armGroupLabels": ["Arm 1: Saxagliptin +Metformin XR/IR", "Arm 2: Placebo +Metformin XR/IR"]}, {"type": "DRUG", "name": "Metformin XR", "description": "Tablet, Oral, 1000 mg -2000 mg, Daily, Day 1 through week 52", "armGroupLabels": ["Arm 1: Saxagliptin +Metformin XR/IR", "Arm 2: Placebo +Metformin XR/IR"]}, {"type": "DRUG", "name": "Saxagliptin", "description": "Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight)", "armGroupLabels": ["Arm 1: Saxagliptin +Metformin XR/IR"], "otherNames": ["BMS-477118"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Change in HbA1c From Baseline to Week 16", "timeFrame": "16 week short term treatment period"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male and female patients eligible if 10 years of age, up to 17 years and 30 weeks of age at the time of screening\n* Previously diagnosed as having type 2 diabetes\n* HbA1c \u22657.0% and \u226410.5%\n* Body weight \u2265 30 kg\n* Stable dose of metformin (\u2265 1000mg - \u2264 2000mg) for a minimum of 2 months\n* Women must have a negative serum or urine pregnancy test\n* Women must not be breastfeeding\n\nExclusion Criteria:\n\n* Current use of anti-diabetic medications or use within the specified timeframe prior to screening (Exception: Metformin)\n* Fasting plasma glucose (FPG) \\> 255 mg/dL\n* Diabetic ketoacidosis (DKA) within 6 months of study entry\n* Abnormal renal function\n* Active liver disease\n* Anemia\n* An abnormal Thyroid Stimulating Hormone (TSH)\n* Creatinine kinase (CK) \u2265 3X ULN", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "10 Years", "maximumAge": "17 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bristol-Myers Squibb", "affiliation": "Bristol-Myers Squibb", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Research Site", "city": "Los Angeles", "state": "California", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Research Site", "city": "Tallahassee", "state": "Florida", "country": "United States", "geoPoint": {"lat": 30.43826, "lon": -84.28073}}, {"facility": "Research Site", "city": "Dearborn", "state": "Michigan", "country": "United States", "geoPoint": {"lat": 42.32226, "lon": -83.17631}}, {"facility": "Research Site", "city": "St. Paul", "state": "Minnesota", "country": "United States", "geoPoint": {"lat": 44.94441, "lon": -93.09327}}, {"facility": "Research Site", "city": "Mineola", "state": "New York", "country": "United States", "geoPoint": {"lat": 40.74927, "lon": -73.64068}}, {"facility": "Research Site", "city": "Cleveland", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Research Site", "city": "Memphis", "state": "Tennessee", "country": "United States", "geoPoint": {"lat": 35.14953, "lon": -90.04898}}, {"facility": "Research Site", "city": "Namur", "country": "Belgium", "geoPoint": {"lat": 50.4669, "lon": 4.86746}}, {"facility": "Research Site", "city": "Calgary", "state": "Alberta", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "Research Site", "city": "Bangalore", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "Research Site", "city": "Aguascalientes", "country": "Mexico", "geoPoint": {"lat": 21.88234, "lon": -102.28259}}, {"facility": "Research Site", "city": "Meridas", "country": "Mexico"}, {"facility": "Research Site", "city": "Monterrey", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Research Site", "city": "Veracruz", "country": "Mexico", "geoPoint": {"lat": 19.18095, "lon": -96.1429}}, {"facility": "Research Site", "city": "Taichung", "country": "Taiwan", "geoPoint": {"lat": 24.1469, "lon": 120.6839}}, {"facility": "Research Site", "city": "Leicester", "country": "United Kingdom", "geoPoint": {"lat": 52.6386, "lon": -1.13169}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Of 32 subjects enrolled, 7 subjects entered the lead-in period. Of these 7 subjects, 6 were randomized", "groups": [{"id": "FG000", "title": "Placebo", "description": "Placebo matching saxagliptin"}, {"id": "FG001", "title": "Saxagliptin", "description": "saxagliptin 2.5 or 5 mg according to body weight"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "Placebo matching saxagliptin"}, {"id": "BG001", "title": "Saxagliptin", "description": "saxagliptin 2.5 or 5 mg according to body weight"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "6"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "6"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "6"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Change in HbA1c From Baseline to Week 16", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage", "timeFrame": "16 week short term treatment period", "groups": [{"id": "OG000", "title": "Saxagliptin", "description": "Saxagliptin 2.5 mg or 5 mg according to bodyweight"}, {"id": "OG001", "title": "Placebo", "description": "Saxagliptin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "0.62"}, {"groupId": "OG001", "value": "0.9", "spread": "0.14"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "52 week", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Placebo matching saxagliptin", "seriousNumAffected": 0, "seriousNumAtRisk": 2, "otherNumAffected": 1, "otherNumAtRisk": 2}, {"id": "EG001", "title": "Saxagliptin", "description": "saxagliptin 2.5 or 5 mg according to body weight", "seriousNumAffected": 0, "seriousNumAtRisk": 4, "otherNumAffected": 4, "otherNumAtRisk": 4}], "otherEvents": [{"term": "Headache", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 4}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 4}]}, {"term": "ABDOMINAL PAIN UPPER", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 4}]}, {"term": "OROPHARYNGEAL PAIN", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 4}]}, {"term": "Pharyngitis Streptococcal", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 4}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 4}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 4}]}, {"term": "Pharyngitis bacterial", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 4}]}, {"term": "LACERATION", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 4}]}, {"term": "URINE OUTPUT INCREASED", "organSystem": "Investigations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 4}]}, {"term": "MENSTRUATION IRREGULAR", "organSystem": "Reproductive system and breast disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 4}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Eva Johnsson, Clinical Science Lead, GLOBAL_MEDICINES_DEV", "organization": "AstraZeneca AB, S-151 85 S\u00f6dert\u00e4lje, Sweden", "email": "Eva.Johnsson@astrazeneca.com", "phone": "+46 31 7762484", "phoneExt": "762 484"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Argentina", "Israel", "Italy", "Russian Federation", "South Africa", "Turkey"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000502994", "term": "Saxagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M228152", "name": "Saxagliptin", "asFound": "Manufacturer", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}